NCT00015834View on ClinicalTrials.gov

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

April 30, 2003

Conditions
Blastic Phase Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveRelapsing Chronic Myelogenous Leukemia
Interventions
DRUG

imatinib mesylate

Given PO

DRUG

cytarabine

Given IV

Trial Locations (1)

90095

University of California at Los Angeles (UCLA ), Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00015834 - STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter